Table 3.
Potential drugs targeting EMT-related modulators in clinical trials.
| Drug | Mechanism of action | Condition or disease | Phase | References |
|---|---|---|---|---|
| Denosumab | Receptor activator of NF-κB ligands (RANKL) | Tenosynovial giant cell tumor | Launched in 2013 | (45) |
| TK-006 | Anti-TNFSF11 (RANKL) | Breast cancer-related bone metastases | I | (46) |
| WO-1066 | STAT3 inhibitors, anti-PD-L1, Janus kinase (JAK) inhibitors | Melanoma, brain cancer | I | (47, 48) |
| DSP-0337 | STAT3 inhibitor | Solid tumors | I | (49) |
| Danvatirsen | STAT3 expression inhibitors | Solid tumors | II | (50, 51) |
| OPB-111077 | STAT3 ligands | Solid tumors | II | (52) |
| Napabucasin | STAT3 inhibitors | Colorectal carcinoma, pancreatic cancer | III | (53, 54) |
| PEGPH20 | HIF1α inhibitors | Metastatic breast cancer | I/II | (55, 56) |
| CRLX-101 | HIF1α inhibitors, DNA Topoisomerase I inhibitors | peritoneum cancer | II | (57, 58) |